medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2023-9-51-56medalphabet-3139Research ArticleСтатьиРоль микробиома в развитии ревматоидного артрита и возможные методы его коррекцииRole of microbioma in rheumatoid arthritis and possible methods of its correctionhttps://orcid.org/0000-0001-5127-611XСпицинаС. С.SpitsinaS. S.

Спицина Светлана Сергеевна, м. н. с., ФГБНУ «Научно-исследовательский институт клинической и экспериментальной ревматологии имени А. Б. Зборовского»; ассистент кафедры госпитальнойтерапии, ВПТ, ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России

Волгоград

Spitsina Svetlana S., junior researcher, Research Institute for Clinical and Experimental Rheumatology n. a. A. B. Zborovsky, Volgograd; assistant at Dept of Hospital Therapy, MFT, Volgograd State Medical University

Volgograd

ssspitsina@mail.ruТинаеваР. Ш.TinaevaR. Sh.

Тинаева Риана Шамильевна, студент

Волгоград

Tinaeva Riana Sh., student

Volgograd

ФГБНУ «Научно-исследовательский институт клинической и экспериментальной ревматологии имени А. Б. Зборовского»; ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава РоссииРоссияResearch Institute for Clinical and Experimental Rheumatology n. a. A. B. Zborovsky, Volgograd; Volgograd State Medical UniversityRussian FederationФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава РоссииРоссияVolgograd State Medical UniversityRussian Federation20232306202309Ревматология в общей врачебной практике (1)5156Copyright © Спицина С.С., Тинаева Р.Ш., 20232023Спицина С.С., Тинаева Р.Ш.Spitsina S.S., Tinaeva R.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3139

Организм человека густонаселен комменсальными и симбиотическими микроорганизмами, геном и экосистемы которых составляют микробиом, присутствие которого регулирует развитие и функцию иммунной системы человека. Кроме того, комменсальные микроорганизмы влияют и на другие физиологические процессы метаболизма хозяина. В последнее время многие ученые акцентируют внимание на важности микробиома в патогенезе ряда заболеваний, в том числе аутоиммунных. Дисбиоз может неблагоприятно влиять на иммунную систему как локально, так и системно, тем самым предрасполагая к некоторым патологиям, включая ревматоидный артрит (РА), при котором уже на ранних стадиях микробиом отличается от такового у здоровых людей. Целью данного обзора является изучение исследований, связывающих изменения микробиома с аутоиммунными механизмами, участвующими в патогенезе РА, и рассмотрение возможных методов их коррекции.

The human body is densely populated by commensal and symbiotic microorganisms whose genome and ecosystems constitute the microbiome whose presence regulates the development and function of the human immune system. In addition, commensal microorganisms influence other physiological processes of the host metabolism. Recently, many scientists have emphasized the importance of the microbiome in the pathogenesis of several diseases, including autoimmune diseases. Dysbiosis can adversely affect the immune system both locally and systemically, thereby predisposing to certain pathologies, including rheumatoid arthritis (RA); in which the microbiome already in its early stages differs from that of healthy individuals. The purpose of this review is to examine the studies linking microbiome changes with autoimmune mechanisms involved in the pathogenesis of RA and to consider possible methods of their correction.

ревматоидный артритмикробиоммикробиота ротовой полостимикробиота кишечникамикробиота легкихаутоиммунное воспалениеrheumatoid arthritismicrobiomeoral microbiotagut microbiotalung microbiotaautoimmune inflammationReferencesSmolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K. Rheumatoid arthritis. Nat Rev Dis Primers. 2018 Feb 8; 4: 18001. https://doi.org/10.1038/nrdp.2018.1Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K. Rheumatoid arthritis. Nat Rev Dis Primers. 2018 Feb 8; 4: 18001. https://doi.org/10.1038/nrdp.2018.1Aletaha D, Ramiro S. Diagnosis and Management of Rheumatoid Arthritis. JAMA. 2018; 320: 1360–1372.Aletaha D, Ramiro S. Diagnosis and Management of Rheumatoid Arthritis. JAMA. 2018; 320: 1360–1372.Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010 Sep 25; 376 (9746): 1094–108. https://doi.org/10.1016/S0140–6736(10)60826–4Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010 Sep 25; 376 (9746): 1094–108. https://doi.org/10.1016/S0140–6736(10)60826–4Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021 Jan; 22 (1): 10–18. https://doi.org/10.1038/s41590–020–00816-xWeyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021 Jan; 22 (1): 10–18. https://doi.org/10.1038/s41590–020–00816-xHansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: Rheumatoid arthritis and gout. Lancet Rheumatol. 2021 Jan; 3 (1): e58–e70. https://doi.org/10.1016/S2665–9913(20)30221–6Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: Rheumatoid arthritis and gout. Lancet Rheumatol. 2021 Jan; 3 (1): e58–e70. https://doi.org/10.1016/S2665–9913(20)30221–6Nerurkar L, Siebert S, McInnes IB, Cavanagh J. Rheumatoid arthritis and depression: An inflammatory perspective. Lancet Psychiatry. 2019 Feb; 6 (2): 164–173. https://doi.org/10.1016/S2215–0366(18)30255–4Nerurkar L, Siebert S, McInnes IB, Cavanagh J. Rheumatoid arthritis and depression: An inflammatory perspective. Lancet Psychiatry. 2019 Feb; 6 (2): 164–173. https://doi.org/10.1016/S2215–0366(18)30255–4Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol. 2014; 10 (6): 329–337. https://doi.org/10.1038/nrrheum.2014.16Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol. 2014; 10 (6): 329–337. https://doi.org/10.1038/nrrheum.2014.16Littlejohn EA, Monrad S. Early Diagnosis and Treatment of Rheumatoid Arthritis. Prim. Care: Clin. Off. Pr. 2018; 45: 237–255. https://doi.org/10.1016/j.pop.2018.02.010Littlejohn EA, Monrad S. Early Diagnosis and Treatment of Rheumatoid Arthritis. Prim. Care: Clin. Off. Pr. 2018; 45: 237–255. https://doi.org/10.1016/j.pop.2018.02.010Hacquard S, et al. Microbiota and host nutrition across plant and animal kingdoms. Cell Host Microbe. 2015; 17: 603–616. https://doi.org/10.1016/j.chom.2015.04.009Hacquard S, et al. Microbiota and host nutrition across plant and animal kingdoms. Cell Host Microbe. 2015; 17: 603–616. https://doi.org/10.1016/j.chom.2015.04.009Lynch JB, Hsiao EY. Microbiomes as sources of emergent host phenotypes. Science. 2019; 365: 1405–1409. https://doi.org/10.1126/science.aay0240Lynch JB, Hsiao EY. Microbiomes as sources of emergent host phenotypes. Science. 2019; 365: 1405–1409. https://doi.org/10.1126/science.aay0240Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018; 33: 570–580. https://doi.org/10.1016/j.ccell.2018.03.015Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018; 33: 570–580. https://doi.org/10.1016/j.ccell.2018.03.015Maeda Y, Takeda K. Host-microbiota interactions in rheumatoid arthritis. Exp. Mol. Med. 2019; 51: 1–6. https://doi.org/10.1038/s12276–019–0283–6Maeda Y, Takeda K. Host-microbiota interactions in rheumatoid arthritis. Exp. Mol. Med. 2019; 51: 1–6. https://doi.org/10.1038/s12276–019–0283–6Main BS, Minter MR. Microbial immuno-communication in neurodegenerative diseases. Front. Neurosci. 2017; 11: 151. https://doi.org/10.3389/fnins.2017.00151Main BS, Minter MR. Microbial immuno-communication in neurodegenerative diseases. Front. Neurosci. 2017; 11: 151. https://doi.org/10.3389/fnins.2017.00151Kundu P, Blacher E, Elinav E, Pettersson S. Our Gut Microbiome: The Evolving Inner Self. Cell. 2017; 171 (7): 1481–1493. https://doi.org/10.1016/j.cell.2017.11.024Kundu P, Blacher E, Elinav E, Pettersson S. Our Gut Microbiome: The Evolving Inner Self. Cell. 2017; 171 (7): 1481–1493. https://doi.org/10.1016/j.cell.2017.11.024Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med. 2019; 25 (3): 377–388. https://doi.org/10.1038/s41591–019–0377–7Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med. 2019; 25 (3): 377–388. https://doi.org/10.1038/s41591–019–0377–7Samriz O, Mizrahi H, Werbner M, Shoenfeld Y, Avni O, Koren O. Microbiota at the crossroads of autoimmunity. Autoimmun Revi. 2016; 15: 859–869. https://doi.org/10.1016/j.autrev.2016.07.012Samriz O, Mizrahi H, Werbner M, Shoenfeld Y, Avni O, Koren O. Microbiota at the crossroads of autoimmunity. Autoimmun Revi. 2016; 15: 859–869. https://doi.org/10.1016/j.autrev.2016.07.012Rinaldi M, Perricone R, Blank M, Perricone C, Shoenfeld Y. Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity. Clin Rev Allerg Immunol. 2013; 45: 152–161. https://doi.org/10.1007/s12016–012–8344–9Rinaldi M, Perricone R, Blank M, Perricone C, Shoenfeld Y. Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity. Clin Rev Allerg Immunol. 2013; 45: 152–161. https://doi.org/10.1007/s12016–012–8344–9Shoenfeld Y, Agmon-Levin N. ASIA – autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011; 36: 4–8. https://doi.org/10.1016/j.jaut.2010.07.003Shoenfeld Y, Agmon-Levin N. ASIA – autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011; 36: 4–8. https://doi.org/10.1016/j.jaut.2010.07.003Marietta E, Horwath I, Balakrishnan B, Taneja V. Role of the intestinal microbiome in autoimmune diseases and its use in treatments. Cell Immunol. 2019; 339: 50–58. https://doi.org/10.1016/j.cellimm.2018.10.005Marietta E, Horwath I, Balakrishnan B, Taneja V. Role of the intestinal microbiome in autoimmune diseases and its use in treatments. Cell Immunol. 2019; 339: 50–58. https://doi.org/10.1016/j.cellimm.2018.10.005Dissick A, Redman RS, Jones M, Rangan BV, Reimold A, Griffiths GR, Mikuls TR, Amdur RL, Richards JS, Kerr GS. Association of periodontitis with rheumatoid arthritis: A pilot study. J Periodontol. 2010; 81 (2): 223–230. https://doi.org/10.1902/jop.2009.090309Dissick A, Redman RS, Jones M, Rangan BV, Reimold A, Griffiths GR, Mikuls TR, Amdur RL, Richards JS, Kerr GS. Association of periodontitis with rheumatoid arthritis: A pilot study. J Periodontol. 2010; 81 (2): 223–230. https://doi.org/10.1902/jop.2009.090309Ortiz P, Bissada NF, Palomo L, Han YW, Al-Zahrani MS, Panneerselvam A, Askari A. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. J Periodontol. 2009; 80 (4): 535–540.Ortiz P, Bissada NF, Palomo L, Han YW, Al-Zahrani MS, Panneerselvam A, Askari A. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. J Periodontol. 2009; 80 (4): 535–540.Farquharson D, Butcher JP, Culshaw S. Periodontitis, porphyromonas, and the pathogenesis of rheumatoid arthritis. Mucosal Immunol. 2012; 5: 112–120. https://doi.org/10.1038/mi.2011.66Farquharson D, Butcher JP, Culshaw S. Periodontitis, porphyromonas, and the pathogenesis of rheumatoid arthritis. Mucosal Immunol. 2012; 5: 112–120. https://doi.org/10.1038/mi.2011.66Mikuls TR, Payne JB, Yu F, Thiele GM, Reynolds RJ, Cannon GW, Markt J, McGowan D, Kerr GS, Redman RS, Reimold A, Griffiths G, Beatty M, Gonzalez SM, Bergman DA, Hamilton BC3rd, Erickson AR, Sokolove J, Robinson WH, Walker C, Chandad F, O'Dell JR. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014; 66 (5): 1090–1100. https://doi.org/10.1002/art.38348.Mikuls TR, Payne JB, Yu F, Thiele GM, Reynolds RJ, Cannon GW, Markt J, McGowan D, Kerr GS, Redman RS, Reimold A, Griffiths G, Beatty M, Gonzalez SM, Bergman DA, Hamilton BC3rd, Erickson AR, Sokolove J, Robinson WH, Walker C, Chandad F, O'Dell JR. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014; 66 (5): 1090–1100. https://doi.org/10.1002/art.38348.Quirke AM, Lugli EB, Wegner N, Hamilton BC, Charles P, Chowdhury M, Ytterberg AJ, Zubarev RA, Potempa J, Culshaw S, Guo Y, Fisher BA, Thiele G, Mikuls TR, Venables PJ. Heightened immune response to autocitrullinated Porphyromonas gingivalis peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis. Ann Rheum Dis. 2014; 73 (1): 263–269. https://doi.org/10.1136/annrheumdis-2012–202726Quirke AM, Lugli EB, Wegner N, Hamilton BC, Charles P, Chowdhury M, Ytterberg AJ, Zubarev RA, Potempa J, Culshaw S, Guo Y, Fisher BA, Thiele G, Mikuls TR, Venables PJ. Heightened immune response to autocitrullinated Porphyromonas gingivalis peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis. Ann Rheum Dis. 2014; 73 (1): 263–269. https://doi.org/10.1136/annrheumdis-2012–202726Wegner N, Wait R, Sroka A, Eick S, Nguyen K-A, Lundberg K, Kinloch AJ, Culshaw S, Potempa J, Venables PJ. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: Implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010; 62: 2662–2672. https://doi.org/10.1002/art.27552Wegner N, Wait R, Sroka A, Eick S, Nguyen K-A, Lundberg K, Kinloch AJ, Culshaw S, Potempa J, Venables PJ. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: Implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010; 62: 2662–2672. https://doi.org/10.1002/art.27552Konig MF, Abusleme L, Reinholdt J, Palmer RJ, Teles RP, Sampson K, Rosen A, Nigrovic PA, Sokolove J, Giles JT, Moutsopoulos NM, Andrade F. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci Transl Med. 2016; 8 (369). https://doi.org/10.1126/scitranslmed.aaj1921Konig MF, Abusleme L, Reinholdt J, Palmer RJ, Teles RP, Sampson K, Rosen A, Nigrovic PA, Sokolove J, Giles JT, Moutsopoulos NM, Andrade F. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci Transl Med. 2016; 8 (369). https://doi.org/10.1126/scitranslmed.aaj1921Caminer AC, Haberman R, Scher JU. Human microbiome, infections, and rheumatic disease. Clin Rheumatol. 2017; 36: 2645–2653. https://doi.org/10.1007/s10067–017–3875–3.Caminer AC, Haberman R, Scher JU. Human microbiome, infections, and rheumatic disease. Clin Rheumatol. 2017; 36: 2645–2653. https://doi.org/10.1007/s10067–017–3875–3.Alpizar-Rodriguez D, Lesker TR, Gronow A, Gilbert B, Raemy E, Lamacchia C, Gabay C, Finckh A, Strowig T. Prevotella copri in individuals at risk for rheumatoid arthritis. Ann Rheum Dis. 2019; 78 (5): 590–593. https://doi.org/10.1136/annrheumdis-2018–214514Alpizar-Rodriguez D, Lesker TR, Gronow A, Gilbert B, Raemy E, Lamacchia C, Gabay C, Finckh A, Strowig T. Prevotella copri in individuals at risk for rheumatoid arthritis. Ann Rheum Dis. 2019; 78 (5): 590–593. https://doi.org/10.1136/annrheumdis-2018–214514Moreno J, et al. Prevotella copri and the microbial pathogenesis of rheumatoid arthritis. Reumatol Clin. 2015; 11: 61–63. https://doi.org/10.1016/j.reuma.2014.11.001Moreno J, et al. Prevotella copri and the microbial pathogenesis of rheumatoid arthritis. Reumatol Clin. 2015; 11: 61–63. https://doi.org/10.1016/j.reuma.2014.11.001Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, Nelson H, Matteson EL, Taneja V. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016; 8 (1): 43. https://doi.org/10.1186/s13073–016–0299–7Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, Nelson H, Matteson EL, Taneja V. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016; 8 (1): 43. https://doi.org/10.1186/s13073–016–0299–7Scher JU, Joshua V, Artacho A, et al. The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome. 2016; 4 (1): 60. https://doi.org/10.1186/s40168–016–0206-xScher JU, Joshua V, Artacho A, et al. The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome. 2016; 4 (1): 60. https://doi.org/10.1186/s40168–016–0206-xRogier R, Evans-Marin H, Manasson J, et al. Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis. Sci Rep. 2017; 7 (1): 15613. https://doi.org/10.1038/s41598–017–15802-xRogier R, Evans-Marin H, Manasson J, et al. Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis. Sci Rep. 2017; 7 (1): 15613. https://doi.org/10.1038/s41598–017–15802-xEricsson AC, Hagan CE, Davis DJ, Franklin CL. Segmented filamentous bacteria: commensal microbes with potential effects on research the immune. Comp Med. 2014; 64: 90–98.Ericsson AC, Hagan CE, Davis DJ, Franklin CL. Segmented filamentous bacteria: commensal microbes with potential effects on research the immune. Comp Med. 2014; 64: 90–98.Willis VC, Demoruelle MK, Derber LA. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum. 2013; 65: 2545–2554. https://doi.org/10.1002/art.38066Willis VC, Demoruelle MK, Derber LA. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum. 2013; 65: 2545–2554. https://doi.org/10.1002/art.38066Reynisdottir G, Karimi R, Joshua V et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2014; 66 (1): 31–39. https://doi.org/10.1002/art.38201Reynisdottir G, Karimi R, Joshua V et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2014; 66 (1): 31–39. https://doi.org/10.1002/art.38201Hart JE, Kallberg H, Laden F et al. Ambient air pollution exposures and risk of rheumatoid arthritis: results from the Swedish EIRA case-control study. Ann Rheum Dis. 2013; 72 (6): 888–894. https://doi.org/10.1136/annrheumdis-2012–201587Hart JE, Kallberg H, Laden F et al. Ambient air pollution exposures and risk of rheumatoid arthritis: results from the Swedish EIRA case-control study. Ann Rheum Dis. 2013; 72 (6): 888–894. https://doi.org/10.1136/annrheumdis-2012–201587Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010; 34 (3): 258–265. https://doi.org/10.1016/j.jaut.2009.12.003Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010; 34 (3): 258–265. https://doi.org/10.1016/j.jaut.2009.12.003Catrina AI, Deane KD, Scher JU. Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. Rheumatology (Oxford). 2016; 55 (3): 391–402. https://doi.org/10.1093/rheumatology/keu469Catrina AI, Deane KD, Scher JU. Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. Rheumatology (Oxford). 2016; 55 (3): 391–402. https://doi.org/10.1093/rheumatology/keu469Kronzer VL, Crowson CS, Sparks JA, Vassallo R, Davis JM 3rd. Investigating Asthma, Allergic Disease, Passive Smoke Exposure, and Risk of Rheumatoid Arthritis. Arthritis Rheumatol. 2019; 71 (8): 1217–1224. https://doi.org/10.1002/art.40858Kronzer VL, Crowson CS, Sparks JA, Vassallo R, Davis JM 3rd. Investigating Asthma, Allergic Disease, Passive Smoke Exposure, and Risk of Rheumatoid Arthritis. Arthritis Rheumatol. 2019; 71 (8): 1217–1224. https://doi.org/10.1002/art.40858Balakrishnan B, Selvaraju V, Chen J, et al. Ethnic variability associating gut and oral microbiome with obesity in children. Gut Microbes. 2021; 13 (1): 1–15. https://doi.org/10.1080/19490976.2021.1882926Balakrishnan B, Selvaraju V, Chen J, et al. Ethnic variability associating gut and oral microbiome with obesity in children. Gut Microbes. 2021; 13 (1): 1–15. https://doi.org/10.1080/19490976.2021.1882926Brandl C, Bucci L, Schett G, Zaiss MM (2021) Crossing the barriers: revisiting the gut feeling in rheumatoid arthritis. Eur J Immunol 51: 798–810.Brandl C, Bucci L, Schett G, Zaiss MM (2021) Crossing the barriers: revisiting the gut feeling in rheumatoid arthritis. Eur J Immunol 51: 798–810.Park J, Kim M, Kang SG, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 2015; 8 (1): 80–93. https://doi.org/10.1038/mi.2014.44Park J, Kim M, Kang SG, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 2015; 8 (1): 80–93. https://doi.org/10.1038/mi.2014.44Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells [published correction appears in Nature. 2014 Feb 13; 506 (7487): 254]. Nature. 2013; 504 (7480): 446–450. https://doi.org/10.1038/nature12721Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells [published correction appears in Nature. 2014 Feb 13; 506 (7487): 254]. Nature. 2013; 504 (7480): 446–450. https://doi.org/10.1038/nature12721Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995; 125 (6): 1401–1412. https://doi.org/10.1093/jn/125.6.1401Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995; 125 (6): 1401–1412. https://doi.org/10.1093/jn/125.6.1401Bindels LB, Delzenne NM, Cani PD, Walter J. Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol. 2015; 12 (5): 303–310. https://doi.org/10.1038/nrgastro.2015.47Bindels LB, Delzenne NM, Cani PD, Walter J. Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol. 2015; 12 (5): 303–310. https://doi.org/10.1038/nrgastro.2015.47Dourado E, Ferro M, Sousa Guerreiro C, Fonseca JE. Diet as a Modulator of Intestinal Microbiota in Rheumatoid Arthritis. Nutrients. 2020; 12 (11): 3504. https://doi.org/10.3390/nu12113504Dourado E, Ferro M, Sousa Guerreiro C, Fonseca JE. Diet as a Modulator of Intestinal Microbiota in Rheumatoid Arthritis. Nutrients. 2020; 12 (11): 3504. https://doi.org/10.3390/nu12113504De Filippis F, Pasolli E, Tett A, et al. Distinct Genetic and Functional Traits of Human Intestinal Prevotella copri Strains Are Associated with Different Habitual Diets. Cell Host Microbe. 2019; 25 (3): 444–453. e3. https://doi.org/10.1016/j.chom.2019.01.004De Filippis F, Pasolli E, Tett A, et al. Distinct Genetic and Functional Traits of Human Intestinal Prevotella copri Strains Are Associated with Different Habitual Diets. Cell Host Microbe. 2019; 25 (3): 444–453. e3. https://doi.org/10.1016/j.chom.2019.01.004Gálvez EJC, Iljazovic A, Amend L, et al. Distinct Polysaccharide Utilization Determines Interspecies Competition between Intestinal Prevotella spp. Cell Host Microbe. 2020; 28 (6): 838–852. e6. https://doi.org/10.1016/j.chom.2020.09.012Gálvez EJC, Iljazovic A, Amend L, et al. Distinct Polysaccharide Utilization Determines Interspecies Competition between Intestinal Prevotella spp. Cell Host Microbe. 2020; 28 (6): 838–852. e6. https://doi.org/10.1016/j.chom.2020.09.012Zhao Y, Wu J, Li JV, Zhou NY, Tang H, Wang Y. Gut microbiota composition modifies fecal metabolic profiles in mice. J Proteome Res. 2013; 12 (6): 2987–2999. https://doi.org/10.1021/pr400263nZhao Y, Wu J, Li JV, Zhou NY, Tang H, Wang Y. Gut microbiota composition modifies fecal metabolic profiles in mice. J Proteome Res. 2013; 12 (6): 2987–2999. https://doi.org/10.1021/pr400263nWeingarden A, González A, Vázquez-Baeza Y, et al. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome. 2015; 3: 10. https://doi.org/10.1186/s40168–015–0070–0.Weingarden A, González A, Vázquez-Baeza Y, et al. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome. 2015; 3: 10. https://doi.org/10.1186/s40168–015–0070–0.Xu MQ, Cao HL, Wang WQ, et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol. 2015; 21 (1): 102–111. https://doi.org/10.3748/wjg.v21.i1.102Xu MQ, Cao HL, Wang WQ, et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol. 2015; 21 (1): 102–111. https://doi.org/10.3748/wjg.v21.i1.102Lee CH, Steiner T, Petrof EO, et al. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients with Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2016; 315 (2): 142–149. https://doi.org/10.1001/jama.2015.18098Lee CH, Steiner T, Petrof EO, et al. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients with Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2016; 315 (2): 142–149. https://doi.org/10.1001/jama.2015.18098Zeng J, Peng L, Zheng W, et al. Fecal microbiota transplantation for rheumatoid arthritis: A case report. Clin Case Rep. 2020; 9 (2): 906–909. https://doi.org/10.1002/ccr3.3677Zeng J, Peng L, Zheng W, et al. Fecal microbiota transplantation for rheumatoid arthritis: A case report. Clin Case Rep. 2020; 9 (2): 906–909. https://doi.org/10.1002/ccr3.3677de Oliveira GLV, Leite AZ, Higuchi BS, Gonzaga MI, Mariano VS. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology. 2017; 152 (1): 1–12. https://doi.org/10.1111/imm.12765de Oliveira GLV, Leite AZ, Higuchi BS, Gonzaga MI, Mariano VS. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology. 2017; 152 (1): 1–12. https://doi.org/10.1111/imm.12765Pineda MD, Thompson SF, Summers K, De Leon F, Pope J, Reid G. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Med Sci Monit 17: CR347–CR354.Pineda MD, Thompson SF, Summers K, De Leon F, Pope J, Reid G. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Med Sci Monit 17: CR347–CR354.Hatakka K, Martio J, Korpela M, et al. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis – a pilot study. Scand J Rheumatol. 2003; 32 (4): 211–215. https://doi.org/10.1080/03009740310003695Hatakka K, Martio J, Korpela M, et al. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis – a pilot study. Scand J Rheumatol. 2003; 32 (4): 211–215. https://doi.org/10.1080/03009740310003695Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, Sharif SK, Asghari-Jafarabadi M, Zavvari S. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition. 2014; 30 (4): 430–435. https://doi.org/10.1016/j.nut.2013.09.007Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, Sharif SK, Asghari-Jafarabadi M, Zavvari S. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition. 2014; 30 (4): 430–435. https://doi.org/10.1016/j.nut.2013.09.007Zamani B, Golkar HR, Farshbaf S, et al. Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial. Int J Rheum Dis. 2016; 19 (9): 869–879. https://doi.org/10.1111/1756–185X.12888Zamani B, Golkar HR, Farshbaf S, et al. Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial. Int J Rheum Dis. 2016; 19 (9): 869–879. https://doi.org/10.1111/1756–185X.12888Alipour B, Homayouni-Rad A, Vaghef-Mehrabany E, et al. Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: A randomized double-blind clinical trial. Int J Rheum Dis. 2014; 17 (5): 519–527. https://doi.org/10.1111/1756–185X.12333Alipour B, Homayouni-Rad A, Vaghef-Mehrabany E, et al. Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: A randomized double-blind clinical trial. Int J Rheum Dis. 2014; 17 (5): 519–527. https://doi.org/10.1111/1756–185X.12333Ferro M, Charneca S, Dourado E, Guerreiro CS, Fonseca JE. Probiotic Supplementation for Rheumatoid Arthritis: A Promising Adjuvant Therapy in the Gut Microbiome Era. Front Pharmacol. 2021; 12: 711788. https://doi.org/10.3389/fphar.2021.711788Ferro M, Charneca S, Dourado E, Guerreiro CS, Fonseca JE. Probiotic Supplementation for Rheumatoid Arthritis: A Promising Adjuvant Therapy in the Gut Microbiome Era. Front Pharmacol. 2021; 12: 711788. https://doi.org/10.3389/fphar.2021.711788Mandel DR, Eichas K, Holmes J. Bacillus coagulans: A viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med. 2010; 10: 1. https://doi.org/10.1186/1472–6882–10–1Mandel DR, Eichas K, Holmes J. Bacillus coagulans: A viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med. 2010; 10: 1. https://doi.org/10.1186/1472–6882–10–1Tannock GW, Munro K, Harmsen HJ, Welling GW, Smart J, Gopal PK. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol. 2000; 66 (6): 2578–2588. https://doi.org/10.1128/AEM.66.6.2578–2588.2000Tannock GW, Munro K, Harmsen HJ, Welling GW, Smart J, Gopal PK. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol. 2000; 66 (6): 2578–2588. https://doi.org/10.1128/AEM.66.6.2578–2588.2000Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000; 289 (5483): 1352–1355. https://doi.org/10.1126/science.289.5483.1352Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000; 289 (5483): 1352–1355. https://doi.org/10.1126/science.289.5483.1352Robert S, Steidler L. Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case. Microb Cell Fact. 2014; 13 Suppl 1 (Suppl 1): S11. https://doi.org/10.1186/1475–2859–13-S1-S11Robert S, Steidler L. Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case. Microb Cell Fact. 2014; 13 Suppl 1 (Suppl 1): S11. https://doi.org/10.1186/1475–2859–13-S1-S11Farrar MD, Whitehead TR, Lan J, et al. Engineering of the gut commensal bacterium Bacteroides ovatus to produce and secrete biologically active murine interleukin-2 in response to xylan. J Appl Microbiol. 2005; 98 (5): 1191–1197. https://doi.org/10.1111/j.1365–2672.2005.02565.xFarrar MD, Whitehead TR, Lan J, et al. Engineering of the gut commensal bacterium Bacteroides ovatus to produce and secrete biologically active murine interleukin-2 in response to xylan. J Appl Microbiol. 2005; 98 (5): 1191–1197. https://doi.org/10.1111/j.1365–2672.2005.02565.xHamady ZZ, Scott N, Farrar MD, et al. Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-β1 under the control of dietary xylan 1. Inflamm Bowel Dis. 2011; 17 (9): 1925–1935. https://doi.org/10.1002/ibd.21565Hamady ZZ, Scott N, Farrar MD, et al. Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-β1 under the control of dietary xylan 1. Inflamm Bowel Dis. 2011; 17 (9): 1925–1935. https://doi.org/10.1002/ibd.21565Maier E, Anderson RC, Roy NC (2015) Understanding how commensal obligate anaerobic bacteria regulate immune functions in the large intestine. Nutrients 7: 45–73.Maier E, Anderson RC, Roy NC (2015) Understanding how commensal obligate anaerobic bacteria regulate immune functions in the large intestine. Nutrients 7: 45–73.Shi N, Zhang SY, Silverman G, Li MT, Cai J, Niu HT. Protective effect of hydroxychloroquine on rheumatoid arthritis-associated atherosclerosis. Animal Mod Exp Med 2: 98–106.Shi N, Zhang SY, Silverman G, Li MT, Cai J, Niu HT. Protective effect of hydroxychloroquine on rheumatoid arthritis-associated atherosclerosis. Animal Mod Exp Med 2: 98–106.Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA. 2013; 110 (22): 9066–9071. https://doi.org/10.1073/pnas.1219451110Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA. 2013; 110 (22): 9066–9071. https://doi.org/10.1073/pnas.1219451110Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog. 2017; 106: 171–181. https://doi.org/10.1016/j.micpath.2016.02.005Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog. 2017; 106: 171–181. https://doi.org/10.1016/j.micpath.2016.02.005Hänninen A, Toivonen R, Pöysti S, et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut. 2018; 67 (8): 1445–1453. https://doi.org/10.1136/gutjnl-2017–314508Hänninen A, Toivonen R, Pöysti S, et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut. 2018; 67 (8): 1445–1453. https://doi.org/10.1136/gutjnl-2017–314508Mccarville JL, Caminero A, Verdu EF (2016) Novel perspectives on therapeutic modulation of the gut microbiota. Ther Adv Gastroenterol 9: 580–593.Mccarville JL, Caminero A, Verdu EF (2016) Novel perspectives on therapeutic modulation of the gut microbiota. Ther Adv Gastroenterol 9: 580–593.Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019; 25 (7): 1096–1103. https://doi.org/10.1038/s41591–019–0495–2Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019; 25 (7): 1096–1103. https://doi.org/10.1038/s41591–019–0495–2Gomez-Gallego C, Pohl S, Salminen S, De Vos WM, Kneifel W. Akkermansia muciniphila: a novel functional microbe with probiotic properties. Benefic Microbes 7: 571–584.Gomez-Gallego C, Pohl S, Salminen S, De Vos WM, Kneifel W. Akkermansia muciniphila: a novel functional microbe with probiotic properties. Benefic Microbes 7: 571–584.Sayers E, MacGregor A, Carding SR. Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis. AIMS Microbiol. 2018; 4 (4): 642–654. https://doi.org/10.3934/microbiol.2018.4.642Sayers E, MacGregor A, Carding SR. Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis. AIMS Microbiol. 2018; 4 (4): 642–654. https://doi.org/10.3934/microbiol.2018.4.642Martin R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, Chain F, Berteau O, Azevedo V, Chatel JM, Sokol H, Bermudez-Humaran LG, Thomas M, Langella P (2017) Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Front Microbiol 8: 226.Martin R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, Chain F, Berteau O, Azevedo V, Chatel JM, Sokol H, Bermudez-Humaran LG, Thomas M, Langella P (2017) Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Front Microbiol 8: 226.Rossi O, van Berkel LA, Chain F, et al. Faecalibacterium prausnitzii A2–165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep. 2016; 6: 18507. https://doi.org/10.1038/srep18507Rossi O, van Berkel LA, Chain F, et al. Faecalibacterium prausnitzii A2–165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep. 2016; 6: 18507. https://doi.org/10.1038/srep18507Zou F, Qiu Y, Huang Y, et al. Effects of short-chain fatty acids in inhibiting HDAC and activating p38 MAPK are critical for promoting B10 cell generation and function. Cell Death Dis. 2021; 12 (6): 582. https://doi.org/10.1038/s41419–021–03880–9Zou F, Qiu Y, Huang Y, et al. Effects of short-chain fatty acids in inhibiting HDAC and activating p38 MAPK are critical for promoting B10 cell generation and function. Cell Death Dis. 2021; 12 (6): 582. https://doi.org/10.1038/s41419–021–03880–9Zhang JB, Huang YJ, Yoon JY, Kemmitt J, Wright C, Schneider K, Sphabmixay P, Hernandez-Gordillo V, Holcomb SJ, Bhushan B, Rohatgi G, Benton K, Carpenter D, Kester JC, Eng G, Breault DT, Yilmaz O, Taketani M, Voigt CA, Carrier RL, Trumper DL, Griffith LG. Primary human colonic mucosal barrier crosstalk with super oxygen-sensitive Faecalibacterium prausnitzii in continuous culture. Med (NY) 2: 74–98. e9.Zhang JB, Huang YJ, Yoon JY, Kemmitt J, Wright C, Schneider K, Sphabmixay P, Hernandez-Gordillo V, Holcomb SJ, Bhushan B, Rohatgi G, Benton K, Carpenter D, Kester JC, Eng G, Breault DT, Yilmaz O, Taketani M, Voigt CA, Carrier RL, Trumper DL, Griffith LG. Primary human colonic mucosal barrier crosstalk with super oxygen-sensitive Faecalibacterium prausnitzii in continuous culture. Med (NY) 2: 74–98. e9.He XY, Zhao SY, Li Y Faecalibacterium prausnitzii: A next-generation probiotic in gut disease improvement. Can J Infect Dis Med Microbiol 2021: 6666114.He XY, Zhao SY, Li Y Faecalibacterium prausnitzii: A next-generation probiotic in gut disease improvement. Can J Infect Dis Med Microbiol 2021: 6666114.Pianta A, Arvikar S, Strle K, et al. Evidence of the Immune Relevance of Prevotella copri, a Gut Microbe, in Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2017; 69 (5): 964–975. https://doi.org/10.1002/art.40003Pianta A, Arvikar S, Strle K, et al. Evidence of the Immune Relevance of Prevotella copri, a Gut Microbe, in Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2017; 69 (5): 964–975. https://doi.org/10.1002/art.40003Artacho A, Isaac S, Nayak R, et al. The Pretreatment Gut Microbiome Is Associated with Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis. Arthritis Rheumatol. 2021; 73 (6): 931–942. https://doi.org/10.1002/art.41622Artacho A, Isaac S, Nayak R, et al. The Pretreatment Gut Microbiome Is Associated with Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis. Arthritis Rheumatol. 2021; 73 (6): 931–942. https://doi.org/10.1002/art.41622Gupta VK, Cunningham KY, Hur B, et al. Gut microbial determinants of clinically important improvement in patients with rheumatoid arthritis. Genome Med. 2021; 13 (1): 149. https://doi.org/10.1186/s13073–021–00957–0Gupta VK, Cunningham KY, Hur B, et al. Gut microbial determinants of clinically important improvement in patients with rheumatoid arthritis. Genome Med. 2021; 13 (1): 149. https://doi.org/10.1186/s13073–021–00957–0

The authors declare that there are no conflicts of interest present.